Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA

Sun Pharmaceutical Industries — Ranbaxy Laboratories — Q1 2012 Earnings Presentation

20 slides from Sun Pharmaceutical Industries's earnings presentation, May 9, 2012

  1. Slide 1: Financial Results: January – March 2012 (Q1)

    Ranbaxy Laboratories Limited FINANCIAL RESULTS: January – March 2012 (Q1) ARUN SAWHNEY CEO & MD Dept. 09 May Name 2012 Post Results Conference Call

  2. Slide 2: Safe Harbor

    Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “p

  3. Slide 3: Key Achievements for Quarter 1, 2012 (Financial)

    1/2 Key Achievements for Quarter 1, 2012 3 Financial  Sales grew 55% over corresponding quarter  Driven by base business and continued strong sales of FTF exclusivity  EBITDA margins, including base business margins improved  Aided by sales growth and focus on cost optimization 736 27% 20% 474 P

  4. Slide 4: Key Achievements for Quarter 1, 2012 (Business)

    2/2 Key Achievements for Quarter 1, 2012 4 Launched Synriam™, 1st ever Business NDA from India on 25 Apr 2012  Emerging market sales $232 Mn Emerging market base business  33% of DF sales contributes 60%+ of total base  Developed market sales $470 Mn business  67% of DF sales  India:  USA: Bas

  5. Slide 5: Functional Performance

    Functional Performance 5 Manufacturing  Started export of Atorvastatin to the US from Mohali SEZ, first DF export from India to the USA in nearly 4 years  Invest for growth:  Malaysia: capacity expansion to address business growth  Nigeria: replacement facility, expected to be online in a year R

  6. Slide 6: Hybrid Business Model

    Hybrid Business Model 6 Synergy with Daiichi Sankyo  Front end:  Ranbaxy marketed Cravit®(Levofloxacin) in Malaysia from Jan 2012  Launched Atorvastatin in Germany with Daiichi Sankyo in Mar 2012  Back end etc.:  Multiple opportunities pursued in development & manufacturing , including intermed

  7. Slide 7: Other Areas

    Other Areas 7 Regulatory  Signed Consent Decree during the Quarter. Progress per plan  Regulatory inspections by 10 country level authorities Derivatives Position  Exposure down to ~$1.50 Bn in Q1 2012 from ~1.62 Bn in Q4 2011. Maturity: ~$40 Mn/Month Debt  Total Debt $815 Mn; Net Debt $44 Mn vs

  8. Slide 8: Financial Performance

    Ranbaxy Laboratories Limited Financial Performance FINANCIAL RESULTS: January – March 2012 (Q1) Dept. 09 May Name 2012 Post Results Conference Call

  9. Slide 9: Sales Performance

    Sales Performance $ Mn Consolidated Sales Q1 2012 736 474 55% Q1 2011 Q1 2012  Robust business growth momentum continued  Growth in sales including base business growth  Aided by sales of exclusivities during the Quarter 9

  10. Slide 10: North America

    North America $ Mn Major markets 416 -USA -Canada 170 145% Q1 2011 Q1 2012  Base business sales in the USA remained strong  Market leader in both the exclusivity products:  Atorvastatin (Lipitor®) and Amlodipine+Atorvastatin (Caduet®) Lipitor® and Caduet® are registered trade-marks of Pfizer 10

  11. Slide 11: India

    India Rs. Mn Major markets 5,002 4,422 -India, CHC $99 Mn -SL $98 Mn 13% Q1 2011 Q1 2012  Robust CHC performance  India business sales performance better than previous quarters, affected by Rupee volatility and slow down in Acute segment 11

  12. Slide 12: Eastern Europe & CIS

    Eastern Europe & CIS $ Mn 62 Major markets 58 -Romania -Russia -Ukraine (6%) Q1 2011 Q1 2012  Romania sales impacted by adverse forex volatility  Terapia is ranked no. 1 in the Gx+ OTC market in Romania  Consistent Russia sales performance 12

  13. Slide 13: Western Europe

    Western Europe $ Mn 43 Major markets 39 -France -Germany -UK 11% Q1 2011 Q1 2012  Pharma liberalization and DS partnership helped achieve strong sales in Italy 13

  14. Slide 14: Asia Pacific & Middle East

    Asia Pacific & Middle East $ Mn 31 Major markets -ANZ -Malaysia 20 59% Q1 2011 Q1 2012  Atorvastatin sales primary drivers for higher sales in ANZ  Malaysia and Myanmar sales performance improved 14

  15. Slide 15: Africa

    Africa $ Mn 45 45 Major markets -South Africa -Nigeria 1% Q1 2011 Q1 2012  Tender sales helped robust performance in Nigeria; South Africa Tender sales impacted  Expanded in Morocco with new manufacturing facility 15

  16. Slide 16: Latin America

    Latin America $ Mn Major markets 16 -Brazil -Mexico 10 (40%) Q1 2011 Q1 2012  Disruption in supply to the region had an adverse impact on sales 16

  17. Slide 17: API & Others

    API & Others $ Mn 34 26 30% Q1 2011 Q1 2012  Nexium API supplies continued  Focused approach on key customers and developed markets 17

  18. Slide 18: Financials Q1 2012: INR Mn

    Financials Q1 2012: INR Mn Q1'11 Particulars Q1'12 Sales 4,474 -Within India 5,085 16,979 - Outside India 31,917 21,453 Sales 37,002 38 Less : Excise duty 48 21,415 Net sales 36,954 727 Other operating income 914 22,142 Total Operating Income 37,868 7,523 Total Consumption 8,922 4,169 Employee cost

  19. Slide 19: Financials Q1 2012: $ Mn

    Financials Q1 2012: $ Mn Q1'11 Particulars Q1'12 Sales 99 -Within India 101 375 - Outside India 635 474 Sales 736 1 Less : Excise duty 1 473 Net sales 735 16 Other operating income 18 489 Total Operating Income 753 166 Total Consumption 177 92 Employee cost 93 137 Other Operating expenses 280 395 To

  20. Slide 20: Questions & Answers

    Questions & Answers Dept. Name

Ranbaxy Laboratories — Q1 2012 Earnings Presentation on 6ix